TZDs and Bone: A Review of the Recent Clinical Evidence
Table 1
Fracture rates comparing rosiglitazone with metformin or glyburide in
ADOPT study. Table adapted from a
Letter to Health Care Providers issued by GSK [4].
Rosiglitazone
Metformin or glyburide
Relative rate (95% CI)
Women
Total followup (P-Y)
2187.20
3578.80
Fracture site
Rate/100PY
Rate/100PY
RR
(95% CI)
Lower limb*
36
1.65
26
0.73
2.27
(1.33, 3.91)
Hip
2
0.09
2
0.06
1.64
(0.12, 22.57)
Foot
22
1.01
11
0.31
3.27
(1.52, 7.47)
Upper limb†
22
1.01
19
0.53
1.89
(0.98, 3.70)
Hand
8
0.37
5
0.14
2.62
(0.76, 10.17)
Humerus
5
0.23
0
0.00
‡
(1.50,‡)
Spine
1
0.05
2
0.06
0.82
(0.01, 15.72)
Other
5
0.23
8
0.22
1.02
(0.26, 3.55)
All fractures
64
2.93
55
1.54
1.90
(1.31, 2.78)
Men
Total followup (P-Y)
2766.70
5570.40
Rate/100PY
Rate/100PY
RR
(95% CI)
Total participants with any fracture
32
1.16
57
1.02
1.13
(0.71, 1.77)
* Hip, foot, ankle, femur, fibula, lower
limb (general), patella, tibia.† Hand, humerus, clavicle, forearm, radius,
upper limb (general), wrist.‡ Cannot estimate. No events in the comparison group.Reprinted with permission from [5]
